Explore

Trendline Trendline
Seragon Biosciences Reports Longevity Drug SRN-901 Extends Lifespan in Mice

Seragon Biosciences Reports Longevity Drug SRN-901 Extends Lifespan in Mice

Seragon Biosciences Reports Longevity Drug SRN-901 Extends Lifespan in Mice
Rapid Read Rapid Read
Study Finds Madecassic Acid May Offer Antibiotic Potential Against Resistant Bacteria

Study Finds Madecassic Acid May Offer Antibiotic Potential Against Resistant Bacteria

Recent research published in RSC Medicinal Chemistry suggests that madecassic acid, a popular ingredient in Korean skincare, may possess antibacterial properties, particularly against antibiotic-resistant E. coli. The study utilized computational screening and lab experiments to demonstrate that madecassic acid binds strongly to the respiratory protein complex cytochrome bd, essential for bacterial survival during infection. This binding inhibits the complex's normal function, potentially killing the bacteria. Researchers isolated madecassic acid from a plant extract in Vietnam and modified it to create variants that inhibited cytochrome bd and shut down bacterial growth. One variant effectively killed E. coli at higher concentrations. Despite these promising findings, experts caution that further research is needed before madecassic acid can be used as an antibiotic.
Trendline Trendline
Wayfinder Biosciences Advances Neurodegeneration Research with Daiichi Sankyo to Second Phase

Wayfinder Biosciences Advances Neurodegeneration Research with Daiichi Sankyo to Second Phase

Wayfinder Biosciences Advances Neurodegeneration Research with Daiichi Sankyo to Second Phase
Trendline Trendline
NorthStar Achieves FDA Acceptance for Actinium-225 Drug Master File, Enhancing Radiopharmaceutical Development

NorthStar Achieves FDA Acceptance for Actinium-225 Drug Master File, Enhancing Radiopharmaceutical Development

NorthStar Achieves FDA Acceptance for Actinium-225 Drug Master File, Enhancing Radiopharmaceutical Development
Rapid Read Rapid Read
FDA Grants RMAT Designation to Grace Science's GS-100 Gene Therapy for NGLY1 Deficiency

FDA Grants RMAT Designation to Grace Science's GS-100 Gene Therapy for NGLY1 Deficiency

The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to GS-100, a gene therapy developed by Grace Science, LLC, for treating NGLY1 Deficiency. This ultra-rare genetic disease affects children and currently has no approved therapies. GS-100 is an investigational adeno-associated viral vector therapy designed to replace the deficient NGLY1 protein. The RMAT designation is based on promising early clinical evidence showing improvements in motor function and cognitive skills in patients treated with GS-100. This designation aims to expedite the development and review process, potentially leading to accelerated approval.
Rapid Read Rapid Read
FDA Considers Lifting Restrictions on Peptides Amid Wellness Trend

FDA Considers Lifting Restrictions on Peptides Amid Wellness Trend

The Food and Drug Administration (FDA) is evaluating the possibility of allowing compounding pharmacies to produce seven peptides that are currently restricted due to safety concerns. This move comes as peptides gain popularity for their purported wellness and anti-aging benefits. Health and Human Services Secretary Robert F. Kennedy Jr. has expressed support for making these peptides more accessible, citing their potential benefits for conditions such as ulcerative colitis, wound healing, and obesity. The FDA's advisory panel on pharmacy compounding is set to discuss these peptides in a meeting scheduled for late July. The agency's previous classification of certain peptides as 'Bulk Drug Substances that Raise Significant Safety Risks' has led to a black market for these substances.
Trendline Trendline
Adcendo Secures $75 Million to Advance Antibody-Drug Conjugate Pipeline for Cancer Treatment

Adcendo Secures $75 Million to Advance Antibody-Drug Conjugate Pipeline for Cancer Treatment

Adcendo Secures $75 Million to Advance Antibody-Drug Conjugate Pipeline for Cancer Treatment
Trendline Trendline
Amazon Web Services Launches AI Platform to Revolutionize Drug Discovery

Amazon Web Services Launches AI Platform to Revolutionize Drug Discovery

Amazon Web Services Launches AI Platform to Revolutionize Drug Discovery
Trendline Trendline
TRIANA Biomedicines Presents TRI-611 at AACR Meeting, Highlighting Potential in Lung Cancer Treatment

TRIANA Biomedicines Presents TRI-611 at AACR Meeting, Highlighting Potential in Lung Cancer Treatment

TRIANA Biomedicines Presents TRI-611 at AACR Meeting, Highlighting Potential in Lung Cancer Treatment
Rapid Read Rapid Read
Research on Senolytic Treatment Shows Promise in Delaying Disc Degeneration in Mice

Research on Senolytic Treatment Shows Promise in Delaying Disc Degeneration in Mice

Recent research has highlighted the potential of senolytic treatments, specifically a combination of Dasatinib and Quercetin (DQ), in delaying early onset intervertebral disc degeneration in SM/J mice. These mice, which naturally exhibit early disc degeneration, were treated with DQ starting at four weeks of age. The study found that DQ treatment led to significant improvements in disc structure and reduced markers of cellular senescence, such as p19 and p21, in the disc tissues. The treatment also decreased systemic inflammation and improved the retention of phenotypic markers in nucleus pulposus (NP) cells, which are crucial for maintaining disc health. The findings suggest that DQ treatment can modulate cellular behavior in the disc microenvironment, potentially offering a therapeutic strategy for disc degeneration.
Rapid Read Rapid Read
New Molecules Offer Hope for Treating Autoimmune Diseases

New Molecules Offer Hope for Treating Autoimmune Diseases

Researchers at Scripps Research Institute have developed a new class of drug compounds called ENDOtollins, which target specific molecular interactions within immune cells to reduce harmful inflammation without compromising the body's ability to fight infections. These compounds disrupt a 'molecular handshake' between two proteins, Munc13-4 and syntaxin 7, which are involved in activating immune sensors within endosomes. This approach offers a more precise treatment for autoimmune diseases like lupus and rheumatoid arthritis, potentially reducing side effects associated with current treatments.
Rapid Read Rapid Read
Scripps Research Develops New Molecules for Autoimmune Disease Treatment

Scripps Research Develops New Molecules for Autoimmune Disease Treatment

Scripps Research scientists have developed a new class of drug compounds called ENDOtollins, which aim to treat autoimmune diseases by reducing harmful inflammation without compromising the body's infection-fighting capabilities. These compounds work by disrupting a specific interaction between two proteins within immune cells, a process described as a 'molecular handshake.' The research, published in Nature Chemical Biology, suggests that these compounds could offer more precise treatment options for conditions like lupus, rheumatoid arthritis, and juvenile arthritis, which affect over 15 million Americans. The study highlights the potential of ENDOtollins to target inflammation pathways specifically, avoiding the broad suppression of the immune system that current treatments often entail.